(S)-3-哌啶乙酸甲酯盐酸盐 | 957471-98-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (S)-3-哌啶乙酸甲酯盐酸盐
• 中文别名: (R)-3-哌啶乙酸甲酯盐酸盐；(R)-2-(3-哌啶基)乙酸甲酯盐酸盐；(R)-哌啶-3-乙酸甲酯盐酸盐；(S)-哌啶基-3-乙酸甲酯盐酸盐
• 英文名称: methyl 2-[(3S)-piperidin-3-yl]acetate hydrochloride
• 英文别名: (S)-methyl 2-(piperidin-3-yl)acetate hydrochloride；methyl 2-[(3S)-piperidin-3-yl]acetate;hydrochloride
• CAS: 957471-98-6
• 化学式: C₈H₁₅NO₂*ClH
• 分子量: 193.674
• InChiKey: BZRVXFSQPBNUIE-FJXQXJEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.97
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  38.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-3-哌啶乙酸甲酯盐酸盐 、 6-chloro-N-cyclohexyl-2-propoxynicotinamide 在 potassium carbonate 作用下， 以 丁腈 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  Discovery of a Potent, Selective, and Orally Bioavailable Acidic 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor: Discovery of 2-[(3S)-1-[5-(Cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic Acid (AZD4017)

  摘要：

  Inhibition of 11 beta-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. We report here the discovery of a nicotinic amide derived carboxylic acid class of inhibitors that has good potency, selectivity, and pharmacokinetic characteristics. Compound 11i (AZD4017) is an effective inhibitor of 11 beta-HSD1 in human adipocytes and exhibits good druglike properties and as a consequence was selected for clinical development.

  DOI：

  10.1021/jm300592r
• 作为试剂：
  描述：

  6-chloro-N-cyclohexyl-2-propylsulfanylpyridine-3-carboxamide 、 (S)-3-哌啶乙酸甲酯盐酸盐 在 (S)-3-哌啶乙酸甲酯盐酸盐 作用下， 以61的产率得到(S)-2-(1-(5-(环己基氨基甲酰基)-6-(丙硫基)吡啶-2-基)哌啶-3-基)乙酸
  参考文献：
  名称：

  J. Med. Chem. 2012, 55, 5951-5964

  摘要：

  DOI：

文献信息

• SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281
  申请人：GILL Adrian Liam

  公开号：US20090264401A1

  公开（公告）日：2009-10-22

  A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

  一种具有化学式（I）的化合物： 及其药用盐，其中变量基团在其中定义；还描述了它们在抑制11βHSD1中的应用，制备它们的方法以及包含它们的药物组合物。
• [EN] BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION BIFONCTIONNELS DE LA KINASE PROGÉNITRICE HÉMATOPOÏÉTIQUE ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：NURIX THERAPEUTICS INC

  公开号：WO2021226262A1

  公开（公告）日：2021-11-11

  The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.

  本公开提供了通过泛素蛋白酶体途径作为HPK1降解剂的双功能化合物，以及治疗受HPK1调节的疾病的方法。
• CHEMICAL COMPOUNDS
  申请人：McCoull William

  公开号：US20080269288A1

  公开（公告）日：2008-10-30

  Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are described.

  公式（I）的化合物：其中变量基团在内部定义；描述了它们在抑制11βHSD1中的应用，制备它们的过程以及包含它们的药物组合物。
• Chemical compounds
  申请人：AstraZeneca AB

  公开号：US07964618B2

  公开（公告）日：2011-06-21

  Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are described.

  本发明描述了公式（I）的化合物，其中变量基团在内部定义；它们在抑制11βHSD1方面的应用，制造它们的过程以及包含它们的制药组合物。
• MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: Highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate
  作者：Ken-ichi Yoshida、Kiyoshi Nakayama、Masami Ohtsuka、Noriko Kuru、Yoshihiro Yokomizo、Atsunobu Sakamoto、Makoto Takemura、Kazuki Hoshino、Hiroko Kanda、Hironobu Nitanai、Kenji Namba、Kumi Yoshida、Yuichiro Imamura、Jason Z. Zhang、Ving J. Lee、William J. Watkins

  DOI：10.1016/j.bmc.2007.07.039

  日期：2007.11

  A series of 4-oxo-4H-pyrido[1,2-a]pyrimidine derivatives, Substituted at the 2-position with piperidines bearing quaternary ammonium salt side chains, were synthesized and evaluated for their ability to potentiate the activity of the fluoroquinolone levofloxacin (LVFX) and the beta-lactam aztreonam (AZT) in Pseudomonas aeruginosa. Attachment of the charged entity using an N-ethylcarbamoyloxy linker led to the discovery of the highly soluble compound 22 (D13-9001), which maintained good potency in vitro and displayed excellent activity in vivo in a rat pneumonia model of P. aeruginosa. (C) 2007 Elsevier Ltd. All rights reserved.